Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Influenza

Free Subscription Articles published in Drug Saf Retrieve available abstracts of 32 articles: HTML format

Single Articles

July 2025
1. ABATE A, Poncato E, Barbieri MA, Powell G, et al
   Off-the-Shelf Large Language Models for Causality Assessment of Individual Case Safety Reports: A Proof-of-Concept with COVID-19 Vaccines.
   Drug Saf. 2025;48:805-820.
   PubMed     Abstract available
   
   
   June 2025
2. ROQUE-PEREIRA L, Sisay MM, Ogar CK, Duran CE, et al
   Comparison of Adverse Events in Pregnant Persons Receiving COVID-19 and Influenza Vaccines: A Disproportionality Analysis Using Combined Data from US VAERS and EudraVigilance Spontaneous Report Databases.
   Drug Saf. 2025 Jun 10. doi: 10.1007/s40264-025-01561.
   PubMed     Abstract available
   
   
   May 2025
3. HAMZAOUI H, Shaum A, Cherkaoui I, Moussa LA, et al
   Assessment of Pharmacovigilance Across University Hospitals in Morocco.
   Drug Saf. 2025;48:527-539.
   PubMed     Abstract available
   
   
   March 2025
4. NAMBASA VP, Gunter HM, Adeyemo MB, Bhawaneedin NY, et al
   Empowering African Expertise: Enhancing Safety Data Integration and Signal Detection for COVID-19 Vaccines Through the African Union Smart Safety Surveillance Joint Signal Management Group.
   Drug Saf. 2025;48:233-249.
   PubMed     Abstract available
   
   
   
5. BOULEFAA D, Bagheri H, Salvo F, Rabier MB, et al
   Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.
   Drug Saf. 2025;48:251-263.
   PubMed     Abstract available
   
   
   November 2024
6. MORCIANO C, Massari M, Cutillo M, Belleudi V, et al
   Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study.
   Drug Saf. 2024;47:1157-1169.
   PubMed     Abstract available
   
   
   October 2024
7. CIAPPONI A, Berrueta M, Argento FJ, Ballivian J, et al
   Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living Systematic Review and Meta-analysis.
   Drug Saf. 2024;47:991-1010.
   PubMed     Abstract available
   
   
   
8. YAN VKC, Yang Y, Wan EYF, Lai FTT, et al
   Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study.
   Drug Saf. 2024;47:1025-1037.
   PubMed     Abstract available
   
   
   
9. BELLITTO C, Luxi N, Ciccimarra F, L'Abbate L, et al
   What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.
   Drug Saf. 2024;47:1011-1023.
   PubMed     Abstract available
   
   
   September 2024
10. WYSZYNSKI DF, Demetriou L, Renz C, Aliabadi S, et al
    Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry.
    Drug Saf. 2024;47:843-851.
    PubMed     Abstract available
    
    
    August 2024
11. GORDILLO-MARANON M, Szmigiel A, Yalmanova V, Caplanusi I, et al
    COVID-19 Vaccines and Heavy Menstrual Bleeding: The Impact of Media Attention on Reporting to EudraVigilance.
    Drug Saf. 2024;47:783-798.
    PubMed     Abstract available
    
    
    July 2024
12. GORDILLO-MARANON M, Candore G, Hedenmalm K, Browne K, et al
    Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination.
    Drug Saf. 2024;47:607-615.
    PubMed     Abstract available
    
    
    June 2024
13. DE LA CUEVA IS, Gerber JE, Hastie A, Brotons C, et al
    Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season.
    Drug Saf. 2024 Jun 29. doi: 10.1007/s40264-024-01456.
    PubMed     Abstract available
    
    
    May 2024
14. CAPLANUSI I, Szmigiel A, van der Elst M, Schougaard Christiansen ML, et al
    The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally.
    Drug Saf. 2024;47:405-418.
    PubMed     Abstract available
    
    
    March 2024
15. DOS SANTOS G, Devadiga R, Kim CS, Bang J, et al
    An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged
    Drug Saf. 2024 Mar 14. doi: 10.1007/s40264-024-01395.
    PubMed     Abstract available
    
    
    
16. WYSZYNSKI DF, Papageorghiou AT, Renz C, Metz TD, et al
    The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations.
    Drug Saf. 2024;47:195-204.
    PubMed     Abstract available
    
    
    February 2024
17. MORO PL, Ennulat C, Brown H, Woody G, et al
    Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
    Drug Saf. 2024 Feb 27. doi: 10.1007/s40264-024-01406.
    PubMed     Abstract available
    
    
    
18. QIN SX, Cheng FWT, Kwok WC, Fung LWY, et al
    Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study.
    Drug Saf. 2024;47:135-146.
    PubMed     Abstract available
    
    
    
19. DONG G, Bate A, Haguinet F, Westman G, et al
    Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing.
    Drug Saf. 2024;47:173-182.
    PubMed     Abstract available
    
    
    December 2023
20. DE GERMAY S, Singier A, Salvo F, Pariente A, et al
    Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
    Drug Saf. 2023;46:1381-1389.
    PubMed     Abstract available
    
    
    November 2023
21. MICALLEF B, Dogne JM, Sultana J, Straus SMJM, et al
    An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance.
    Drug Saf. 2023;46:1089-1103.
    PubMed     Abstract available
    
    
    October 2023
22. SLINGERLAND P, van Hunsel FPAM, Lieber T, van Balveren L, et al
    The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands.
    Drug Saf. 2023 Oct 26. doi: 10.1007/s40264-023-01356.
    PubMed     Abstract available
    
    
    September 2023
23. WALTON M, Pletzer V, Teunissen T, Lumley T, et al
    Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.
    Drug Saf. 2023;46:867-879.
    PubMed     Abstract available
    
    
    June 2023
24. KAUR U, Fatima Z, Maheshwari K, Sahni V, et al
    Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
    Drug Saf. 2023;46:553-563.
    PubMed     Abstract available
    
    
    
25. AHMADIZAR F, Luxi N, Raethke M, Schmikli S, et al
    Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials.
    Drug Saf. 2023;46:575-585.
    PubMed     Abstract available
    
    
    May 2023
26. KRALOVA K, Wilson CA, Richebourg N, D'souza J, et al
    Quality of MedDRA((R)) Coding in a Sample of COVID-19 Vaccine Medication Error Data.
    Drug Saf. 2023;46:501-507.
    PubMed     Abstract available
    
    
    April 2023
27. BAUCHAU V, Davis K, Frise S, Jouquelet-Royer C, et al
    Real-World Monitoring of COVID-19 Vaccines: An Industry Expert View on the Successes, Challenges, and Future Opportunities.
    Drug Saf. 2023;46:327-333.
    PubMed     Abstract available
    
    
    
28. RAETHKE M, van Hunsel F, Thurin NH, Dureau-Pournin C, et al
    Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose.
    Drug Saf. 2023;46:391-404.
    PubMed     Abstract available
    
    
    
29. OGAR CK, Quick J, Gilbert HN, Vreman RA, et al
    Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.
    Drug Saf. 2023;46:357-370.
    PubMed     Abstract available
    
    
    March 2023
30. KALKNER KM, Sundstrom A, Nurminen ML, Larsson M, et al
    Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency.
    Drug Saf. 2023;46:319-321.
    PubMed    
    
    
    
31. WYSZYNSKI DF, Bhattacharya M, Martinez-Perez O, Scialli AR, et al
    The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER): Protocol and Methodological Considerations.
    Drug Saf. 2023;46:297-308.
    PubMed     Abstract available
    
    
    
32. ZAPATA-CACHAFEIRO M, Prieto-Campo A, Portela-Romero M, Carracedo-Martinez E, et al
    Effect of Previous Anticoagulant Treatment on Risk of COVID-19.
    Drug Saf. 2023;46:273-281.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.